DiaMedica Secures Health Canada Approval for Preeclampsia Study, Advances Stroke Trial, Extends Cash Runway to 2027
DMAC has more than doubled off its 52-week low of $3.19.
Summary
DiaMedica Therapeutics reported full-year 2025 financial results alongside significant clinical and operational updates. The company received Health Canada regulatory approval to initiate a Phase 2 study for DM199 in early-onset preeclampsia, a key pipeline expansion. Additionally, its ReMEDy2 Phase 2/3 acute ischemic stroke trial is nearing a critical milestone, approaching 70% of required interim enrollment with analysis slated for the second half of 2026. Financially, DiaMedica reported $59.9 million in cash and short-term investments as of December 31, 2025, providing an anticipated operational runway through the second half of 2027. This strong cash position, resulting from prior financing activities, significantly de-risks the company's ability to fund its ongoing clinical programs. These developments are highly positive, indicating strong progress across its therapeutic pipeline and enhanced financial stability, which are crucial for a clinical-stage biotech. Traders should monitor the upcoming interim analysis for the ReMEDy2 trial and further updates on the preeclampsia studies.
At the time of this announcement, DMAC was trading at $6.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $345.8M. The 52-week trading range was $3.19 to $10.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.